-
公开(公告)号：US20230130858A1
公开(公告)日：2023-04-27
申请号：US17880160
申请日：2022-08-03
Applicant: TOOLGEN INCORPORATED
Inventor： Young-Hoon KIM , Min Hee JUNG , Joonsun LEE , Eunji SHIN , Kang In LEE , Seokjoong KIM , Jeongjoon LEE
Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
-
公开(公告)号：US20250064861A1
公开(公告)日：2025-02-27
申请号：US18944148
申请日：2024-11-12
Applicant: TOOLGEN INCORPORATED
Inventor： Jae Young LEE , Chang Hyun AHN , Kang In LEE , Yu Ri CHOI
IPC: A61K35/39 , A61K35/407 , C12N5/071
Abstract: The present disclosure relates to cells for intravascular transplantation having hemocompatibility in which the blood coagulation mechanism and thrombosis reaction are inhibited by artificially modifying the F3 gene encoding CD142 that is an initiator of blood coagulation, using gene scissors technology to reduce or suppress the expression or activity of CD142, a method of producing the same, and a use thereof for preventing or treating liver disease and diabetes.
-
公开(公告)号：US20230063739A1
公开(公告)日：2023-03-02
申请号：US17792203
申请日：2021-01-14
Applicant: TOOLGEN INCORPORATED
Inventor： Eun Ji SHIN , Kang In LEE , Jae Young LEE
IPC: C12N5/0775 , C12N15/11 , C12N9/22 , C12N15/90
Abstract: The present application relates to cells having high adaptability under hypoxic conditions and to a preparation method therefor. Particularly, the present disclosure provides cells having high adaptability under hypoxic conditions, the cells including at least one engineered gene having an indel within a wild-type gene selected from the group consisting of HIF1AN, HIF3A, PHD2, TLR4 and PAI1. In addition, the present disclosure provides, as a method for preparing cells having high adaptability under hypoxic conditions, a gene editing method including introducing a CRISPR/Cas9 system into cells.
-
Patent Agency Ranking
公开(公告)号：US20250000912A1
公开(公告)日：2025-01-02
申请号：US18822009
申请日：2024-08-30
Applicant: TOOLGEN INCORPORATED
Inventor： Jae Young LEE , Kang In LEE , Young Ju SON , Nan Yeong GO , Eun Ji SHIN , Hwan Yeul YU
Abstract: Hypoimmunogenic stem cells and hypoimmunogenic cells differentiated or derived from stem cells are disclosed. The hypoimmunogenic stem cells and the hypoimmunogenic cells differentiated or derived therefrom are capable of inhibiting immune rejection upon transplantation by increasing the expression or activity level of immune activity inhibitory factors. A method of preparing the same and a cell therapeutic agent using the same are also disclosed.
-
公开(公告)号：US20240166999A1
公开(公告)日：2024-05-23
申请号：US18424920
申请日：2024-01-29
Applicant: TOOLGEN INCORPORATED
Inventor： Eun Ji SHIN , Kang In LEE , Yu Ri CHOI , Hye Jung SHIN , Jae Young LEE , Hwan Yeul YU
IPC: C12N5/0775 , C12N9/16 , C12N15/11 , C12N15/86
CPC classification number: C12N5/0665 , C12N9/16 , C12N15/11 , C12N15/86 , C12N2310/20 , C12N2510/00 , C12Y301/00
Abstract: Mesenchymal stem cells, a preparation method therefor, and a cell therapeutic agent using same have hemocompatibility since thrombosis thereof is suppressed after the expression or activation level of blood coagulation initiating factor CD142 is reduced or inhibited. When intravascularly administered, the mesenchymal stem cells have improved hemocompatibility since thrombosis thereof, which can be caused by the administered mesenchymal stem cells, is suppressed.
-
6.发明公开公开(公告)号：US20240139254A1
公开(公告)日：2024-05-02
申请号：US18407597
申请日：2024-01-09
Applicant: TOOLGEN INCORPORATED
Inventor： Eun Ji SHIN , Kang In LEE , Yu Ri CHOI , Hye Jung SHIN , Jae Young LEE
IPC: A61K35/28 , C12N5/0775 , C12N9/22 , C12N15/113
CPC classification number: A61K35/28 , C12N5/0662 , C12N9/22 , C12N15/113 , C12N2310/20
Abstract: Provided are mesenchymal stem cells, a preparation method therefor, and a use thereof, the mesenchymal stem cell having oxidative stress resistance by reducing or inhibiting the expression or activity level of KEAP1, which is a negative regulator of Nrf2, so as to increase the activity of Nrf2.
-
公开(公告)号：US20230053781A1
公开(公告)日：2023-02-23
申请号：US17792771
申请日：2021-01-14
Inventor： Eun Ji SHIN , Kang In LEE , Nahee LEE , Jong Wook CHANG , Na Kyung LEE , Duk Lyul NA , Jae Young LEE
Abstract: The present disclosure provides a pharmaceutical composition for treating Alzheimer's disease and use thereof, the pharmaceutical composition containing, as an active ingredient, stem cells (SC) having high adaptability under hypoxic conditions. Particularly, the present disclosure discloses a pharmaceutical composition for alleviating or treating the symptoms of Alzheimer's disease, the pharmaceutical composition containing, as an active ingredient, mesenchymal stem cells (MSC) which have high adaptability or viability in hypoxic environments and comprise one or more knock-out HIF1AN genes.
-
公开(公告)号：US20200149022A1
公开(公告)日：2020-05-14
申请号：US16628199
申请日：2018-07-06
Applicant: TOOLGEN INCORPORATED
Inventor： Young-Hoon KIM , Min Hee JUNG , Joonsun LEE , Eunji SHIN , Kang In LEE , Seokjoong KIM , Jeongjoon LEE
Abstract: The present invention relates to an artificially engineered CRISPR/Cas9 system. More particularly, the present invention relates to an artificially engineered CRISPR enzyme having enhanced target specificity and a use of an artificially engineered CRISPR/Cas9 system including the same enzyme in genome and/or epigenome manipulation or modification, genome targeting, genome editing, and in vitro diagnosis, etc.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.014 seconds)
